Arcturus Therapeutics Holdings Inc at Canaccord Genuity Growth Conference Transcript
Hi, everyone. Hi, everyone. Welcome and thanks for attending Canaccord Genuity's 43rd Annual Growth Conference. My name is Joohwan Kim, and I'm an associate on Whitney Ijem's genetic medicine and rare disease team. We're very excited to have the team from Arcturus Therapeutics here. It's my great pleasure to introduce the President and CEO, Mr. Joseph Payne. Arcturus is a global-stage mRNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. And so with that, I'll turn it over to the team for their presentation.
All right, thank you. We'll go ahead. That was an appropriate introduction. The Arcturus is a messenger RNA medicines and vaccines company. I remember a couple of years ago, we used to spend quite a bit of time explaining what messenger RNA is. But now, because of the COVID pandemic, and everyone's been vaccinated, there's a lot more
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
